MicroRNA-18b is upregulated in breast cancer and modulates genes involved in cell migration

Oncology Reports

Volumn 30, Issue 5, 2013, Pages 2399-2410

  Fonseca Sanchéz, Miguel A ^a   Pérez Plasencia, Carlos ^a,b   Fernández Retana, Jorge ^b   Arechaga Ocampo, Elena ^b   Marchat, Laurence A ^c   Rodríguez Cuevas, Sergio ^d   Bautista Piña, Veronica ^d   Arellano Anaya, Zaira E ^a   Flores Pérez, Ali ^a   Diaz Chávez, José ^b   López Camarillo, César ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^d Institute of Breast Diseases FUCAM   (Mexico)

Author keywords

Breast cancer; Cell migration; Expression profiling; MicroRNA 18b; Transcriptome; Tumor marker

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EXONUCLEASE; HOMEODOMAIN PROTEIN; KALLIKREIN 6; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MICRORNA; MICRORNA 18B; MUSCARINIC RECEPTOR; OLFACTORY MARKER PROTEIN; POTASSIUM CHANNEL; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; VOLTAGE GATED SODIUM CHANNEL BETA SUBUNIT;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TISSUE; CEACAM5 GENE; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; CRX GENE; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE INDUCTION; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; KIR3DL3 GENE; KLK3 GENE; MAGED4B GENE; METASTASIS; NLRP7 GENE; OLFM3 GENE; ONCOGENE; OR GENE; POSTN GENE; PRIORITY JOURNAL; RNA ANALYSIS; SEMG1 GENE; UPREGULATION;

BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MICRORNAS; NEOPLASM METASTASIS; UP-REGULATION;

EID: 84885067586     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2691     Document Type: Article

References (88)

1. Hammond SM: RNAi, microRNAs, and human disease. Cancer Chemother Pharmacol 58: S63-S68, 2006.
2. Tanzer A and Stadler PF: Molecular evolution of a microRNA cluster. J Mol Biol 339: 327-335, 2004.
3. Mendell JT: miRiad roles for the miR-17-92 cluster in development and disease. Cell 133: 217-222, 2008.
4. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, Newman J, Bronson RT, Crowley D, Stone JR, Jaenisch R, Sharp PA and Jacks T: Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 132: 875-886, 2008.
5. Tatsuguchi M, Seok HY, Callis TE, Thomson JM, Chen JF, Newman M, Rojas M, Hammond SM and Wang DZ: Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol 42: 1137-1141, 2007.
6. Otaegui D, Baranzini SE, Armañanzas R, Calvo B, Muñoz-Culla M, Khankhanian P, Inza I, Lozano JA, Castillo-Triviño T, Asensio A, Olaskoaga J and López de Munain A: Differential micro RNA expression in PBMC from múltiple sclerosis patients. PloS One 4: e6309, 2009.
7. Zhang ZZ, Liu X, Wang DQ, Teng MK, Niu LW, Huang AL and Liang Z: Hepatitis B virus and hepatocellular carcinoma at the miRNA level. World J Gastroenterol 17: 3353-3358, 2011.
8. Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D and Wang Y: Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol 24: 652-657, 2009.
9. Kim TH, Kim YK, Kwon Y, Heo JH, Kang H, Kim G and An HJ: Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology 57: 734-743, 2010.
10. Sand M, Skrygan M, Sand D, Georgas D, Hahn SA, Gambichler T, Altmeyer P and Bechara FG: Expression of microRNAs in basal cell carcinoma. Br J Dermatol 167: 847-855, 2012.
11. Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM and Gao HJ: Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis 11: 50-54, 2010.
12. He X, DiMeco F, Vescovi A, Heth J, Muraszko K and Fan X: MIR-18b regulates glioblastoma neurosphere growth through NOTCH2, NEDD9, and MEKK1. Neuro Oncol 14 (Suppl 6): vi142-vi152, 2012.
13. Leivonen SK, Mäkelä R, Ostling P, Kohonen P, Haapa-Paananen S, Kleivi K, Enerly E, Aakula A, Hellström K, Sahlberg N, Kristensen VN, Børresen-Dale AL, Saviranta P, Perälä M and Kallioniemi O: Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene 28: 3926-3936, 2009.
14. Yoshimoto N, Toyama T, Takahashi S, Sugiura H, Endo Y, Iwasa M, Fujii Y and Yamashita H: Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer. Breast Cancer Res Treat 130: 331-339, 2011.
15. Cookson VJ, Bentley MA, Hogan BV, Horgan K, Hayward BE, Hazelwood LD and Hughes TA: Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNA within the tumours. Cell Oncol 35: 301-308, 2012.
16. Simon A and Biot E: ANAIS: Analysis of NimbleGen arrays interface. Bioinformatics 26: 2468-2469, 2010.
17. Kang N and Koo J: Olfactory receptors in non-chemosensory tissues. BMB Rep 5: 612-622, 2012.
18. Neuhaus EM, Zhang W, Gelis L, Deng Y, Noldus J and Hatt H: Activation of an olfactory receptor inhibits proliferation of prostate cancer cells. J Biol Chem 284: 16218-16225, 2009.
19. Zhang W, Edwards A, Fan W, Flemington EK and Zhang K: miRNA-mRNA correlation-network modules in human prostate cancer and the differences between primary and metastatic tumor subtypes. PLoS One 7: e40130, 2012.
20. Betel D, Wilson M, Gabow A, Marks DS and Sander C: The microRNA.org resource: targets and expression. Nucleic Acids Res 36: 149-153, 2008.
21. Plessy C, Pascarella G, Bertin N, Akalin A, Carrieri C, Vassalli A, Lazarevic D, Severin J, Vlachouli C, Simone R, Faulkner GJ, Kawai J, Daub CO, Zucchelli S, Hayashizaki Y, Mombaerts P, Lenhard B, Gustincich S and Carninci P: Promoter architecture of mouse olfactory receptor genes. Genome Res 22: 486-497, 2012.
22. Clements J, Ward G, Kaushal A, Hi SI, Kennett C and Nicol D: A prostate-specific antigen-like protein associated with renal cell carcinoma in women. Clin Cancer Res 3: 1427-1431, 1997.
23. Majumdar S and Diamandis EP: The promoter and the enhancer region of the KLK3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines. Br J Cancer 79: 1594-1602, 1999.
24. Takeshita S, Kikuno R, Tezuka K and Amann E: Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J 15: 271-278, 1993.
25. Horiuchi K, Amizuka N, Takeshita S, Takamatsu H, Katsuura M, Ozawa H, Toyama Y, Bonewald LF and Kudo A: Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J Bone Miner Res 14: 1239-1249, 1999.
26. Siriwardena BS, Kudo Y, Ogawa I, Kitagawa M, Kitajima S, Hatano H, Tilakaratne WM, Miyauchi M and Takata T: Periostin is frequently overexpressed and enhances invasion and angiogenesis in oral cancer. Br J Cancer 95: 1396-1403, 2006.
27. Jonsdottir K, Janssen SR, Da Rosa FC, Gudlaugsson E, Skaland I, Baak JP and Janssen EA: Validation of expression patterns for nine miRNAs in 204 lymph-node negative breast cancers. PLoS One 7: e48692, 2012.
28. Fornier M and Fumoleau P: The paradox of triple negative breast cancer: novel approaches to treatment. Breast J 1: 41-51, 2012.
29. Dreyer WJ: The area code hypothesis revisited: olfactory receptors and other related transmembrane receptors may function as the last digits in a cell surface code for assembling embryos. Proc Natl Acad Sci USA 95: 9072-9077, 1998.
30. Goto T, Salpekar A and Monk M: Expression of a testis-specific member of the olfactory receptor gene family in human primordial germ cells. Mol Hum Reprod 7: 553-558, 2001.
31. Weng J, Wang J, Hu X, Wang F, Ittmann M and Liu M: PSGR2, a novel G-protein coupled receptor, is overexpressed in human prostate cancer. Int J Cancer 118: 1471-1480, 2006.
32. McIntyre A, Summersgill B, Jafer O, Rodriguez S, Zafarana G, Oosterhuis JW, Gillis AJ, Looijenga L, Cooper C, Huddart R, Clark J and Shipley J: Defining minimum genomic regions of imbalance involved in testicular germ cell tumors of adolescents and adults through genome wide microarray analysis of cDNA clones. Oncogene 23: 9142-9147, 2004.
33. Raish M, Khurshid M, Ansari MA, Chaturvedi PK, Bae SM, Kim JH, Park EK, Park DC and Ahn WS: Analysis of molecular cytogenetic alterations in uterine leiomyosarcoma by array-based comparative genomic hybridization. J Cancer Res Clin Oncol 138: 1173-1186, 2012.
34. Muranen TA, Greco D, Fagerholm R, et al: Breast tumors from CHEK2 110delC-mutation carriers: genomic landscape and clinical implications. Breast Cancer Res 13: R90, 2011.
35. Wescott MP, Rovira M, Reichert M, von Burstin J, Means A, Leach SD and Rustgi AK: Pancreatic ductal morphogenesis and the Pdx1 homeodomain transcription factor. Mol Biol Cell 20: 4838-4844, 2009.
36. Sakai H, Eishi Y, Li XL, Akiyama Y, Miyake S, Takizawa T, Konishi N, Tatematsu M, Koike M and Yuasa Y: PDX1 homeobox protein expression in pseudopyloric glands and gastric carcinomas. Gut 53: 323-330, 2004.
37. Ma J, Chen M, Wang J, Xia HH, Zhu S, Liang Y, Gu Q, Qiao L, Dai Y, Zou B, Li Z, Zhang Y, Lan H and Wong BC: Pancreatic duodenal homeobox-1 (PDX1) functions as a tumor suppressor in gastric cancer. Carcinogenesis 29: 1327-1333, 2008.
38. Galmiche L, Sarnacki S, Verkarre V, Boizet B, Duvillie B, Fabre M and Jaubert F: Transcription factors involved in pancreas development are expressed in paediatric solid pseudopapillary tumours. Histopathology 53: 318-324, 2008.
39. Park JY, Hong SM, Klimstra DS, Goggins MG, Maitra A and Hruban RH: Pdx1 expression in pancreatic precursor lesions and neoplasms. Appl Immunohistochem Mol Morphol 19: 444-449, 2011.
40. Nakata T, Kitamura Y, Shimizu K, Tanaka S, Fujimori M, Yokoyama S, Ito K and Emi M: Fusion of a novel gene, ELKS, to RET due to translocation t(10;12)(q11;p13) in a papillary thyroid carcinoma. Genes Chromosomes Cancer 25: 97-103, 1999.
41. Bakker AB, Phillips JH, Figdor CG and Lanier LL: Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL. J Immunol 160: 5239-5245, 1998.
42. Maat W, van der Slik AR, Verhoeven DH, Alizadeh BZ, Ly LV, Verduijn W, Luyten GP, Mulder A, van Hall T, Koning F, Jager MJ and van Bergen J: Evidence for natural killer cell-mediated protection from metastasis formation in uveal melanoma patients. Invest Ophthalmol Vis Sci 50: 2888-2895, 2009.
43. Okada K, Hirota E, Mizutani Y, Fujioka T, Shuin T, Miki T, Nakamura Y and Katagiri T: Oncogenic role of NALP7 in testicular seminomas. Cancer Sci 95: 949-954, 2004.
44. Ohno S, Kinoshita T, Ohno Y, Minamoto T, Suzuki N, Inoue M and Suda T: Expression of NLRP7 (PYPAF3, NALP7) protein in endometrial cancer tissues. Anticancer Res 28: 2493-2498, 2008.
45. Coma M, Vicente R, Busquets S, Carbó N, Tamkun MM, López-Soriano FJ, Argilés JM and Felipe A: Impaired voltage-gated K+ channel expression in brain during experimental cancer cachexia. FEBS Lett 536: 45-50, 2003.
46. Usami S, Motoyama S, Koyota S, Wang J, Hayashi-Shibuya K, Maruyama K, Takahashi N, Saito H, Minamiya Y, Takasawa S, Ogawa J and Sugiyama T: Regenerating gene I regulates interleukin-6 production in squamous esophageal cancer cells. Biochem Biophys Res Commun 29: 4-8, 2010.
47. Hayashi K, Motoyama S, Koyota S, Koizumi Y, Wang J, Takasawa S, Itaya-Hironaka A, Sakuramoto-Tsuchida S, Maruyama K, Saito H, Minamiya Y, Ogawa J and Sugiyama T: REG I enhances chemo- and radiosensitivity in squamous cell esophageal cancer cells. Cancer Sci 99: 2491-2495, 2008.
48. Wiśniewski A, Jankowska R, Passowicz-Muszyńska E, Wiśniewska E, Majorczyk E, Nowak I, Frydecka I and Kuśnierczyk P: KIR2DL2/S2 and HLA-C C1C1 genotype is associated with better response to treatment and prolonged survival of patients with non-small cell lung cancer in a Polish Caucasian population. Hum Immunol 73: 927-931, 2012.
49. Almalte Z, Samarani S, Iannello A, Debbeche O, Duval M, Infante-Rivard C, Amre DK, Sinnett D and Ahmad A: Novel associations between activating killer-cell immunoglobulin-like receptor genes and childhood leukemia. Blood 118: 1323-1328, 2011.
50. Cumming AP, Hopmans SN, Vukmirović-Popović S and Duivenvoorden WC: PSA affects prostate cancer cell invasion in vitro and induces an osteoblastic phenotype in bone in vivo. Prostate Cancer Prostatic Dis 14: 286-294, 2011.
51. Mattsson JM, Närvänen A, Stenman UH and Koistinen H: Peptides binding to prostate-specific antigen enhances its antiangiogenic activity. Prostate 72: 1588-1594, 2012.
52. Saxena P, Trerotola M, Wang T, Li J, Sayeed A, Vanoudenhove J, Adams DS, Fitzgerald TJ, Altieri DC and Languino LR: PSA regulates androgen receptor expression in prostate cancer cells. Prostate 72: 769-776, 2012.
53. O'Mara TA, Nagle CM, Batra J, Kedda MA, Clements JA and Spurdle AB: Kallikrein-related peptidase 3 (KLK3/PSA) single nucleotide polymorphisms and ovarían cancer survival. Twin Res Hum Genet 14: 323-327, 2011.
54. Black MH and Diamandis EP: The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast. Breast Cancer Res Treat 59: 1-14, 2000.
55. Szczepanski MJ, DeLeo AB, Łuczak M, Molinska-Glura M, Misiak J, Szarzynska B, Dworacki G, Zagor M, Rozwadowska N, Kurpisz M, Krzeski A, Kruk-Zagajewska A, Kopec T, Banaszewski J and Whiteside TL: PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions. Oral Oncol 49: 144-151, 2012.
56. Español AJ and Sales MN: Different muscarinic receptors are involved in the proliferation of murine mammary adenocarcinoma cell lines. Int J Mol Med 13: 311-317, 2004.
57. Fiszman GL, Middonno MC, de la Torre E, Farina M, Español AJ and Sales ME: Activation of muscarinic cholinergic receptors induces MCF-7 cells proliferation and angiogenesis by stimulating nitric oxide synthase activity. Cancer Biol Ther 6: 1106-1113, 2007.
58. Español AJ, de la Torre E, Fiszman GL and Sales ME: Role of non-neuronal cholinergic system in breast cancer progression. Life Sci 80: 2281-2285, 2007.
59. Ferretti M, Fabbiano C, Di Bari M, Ponti D, Calogero A and Tata AM: M2 muscarinic receptors inhibit cell proliferation in human glioblastoma cell lines. Life Sci 91: 1134-1137, 2012.
60. Cabadak H, Aydin B and Kan B: Regulation of M2, M3, and M4 muscarinic receptor expression in K562 chronic myelogenous leukemic cells by carbachol. J Recept Signal Transduct Res 31: 26-32, 2011.
61. Keenan J, Joyce H, Aherne S, O'Dea S, Doolan P, Lynch V and Clynes M: Olfactomedin III expression contributes to anoikis-resistance in clonal variants of a human lung squamous carcinoma cell line. Exp Cell Res 318: 593-602, 2012.
62. Miljkovic-Licina M, Hammel P, Garrido-Urbani S, Lee BP, Meguenani M, Chaabane C, Bochaton-Piallat ML and Imhof BA: Targeting olfactomedin-like 3 inhibits tumor growth by impairing angiogenesis and pericyte coverage. Mol Cancer Ther 11: 2588-2599, 2012.
63. Rouget-Quermalet V, Giustiniani J, Marie-Cardine A, Beaud G, Besnard F, Loyaux D, Ferrara P, Leroy K, Shimizu N, Gaulard P, Bensussan A and Schmitt C: Protocadherin 15 (PCDH15): a new secreted isoform and a potential marker for NK/T cell lymphomas. Oncogene 25: 2807-2811, 2006.
64. Adachi K, Toyota M, Sasaki Y, Yamashita T, Ishida S, Ohe-Toyota M, Maruyama R, Hinoda Y, Saito T, Imai K, Kudo R and Tokino T: Identification of SCN3B as a novel p53-inducible proapoptotic gene. Oncogene 23: 7791-7798, 2004.
65. Rodrigues RG, Panizo-Santos A, Cashel JA, Krutzsch HC, Merino MJ and Roberts DD: Semenogelins are ectopically expressed in small cell lung carcinoma. Clin Cancer Res 7: 854-860, 2001.
66. Zhang Y, Wang Z, Zhang J, Farmer B and Lim SH: Semenogelin I expression in myeloma cells can be upregulated pharmacologically. Leuk Res 32: 1889-1894, 2008.
67. Hienonen T, Sammalkorpi H, Enholm S, Alhopuro P, Barber TD, Lehtonen R, Nupponen NN, Lehtonen H, Salovaara R, Mecklin JP, Järvinen H, Koistinen R, Arango D, Launonen V, Vogelstein B, Karhu A and Aaltonen LA: Mutations in two short noncoding mononucleotide repeats in most microsatellite-unstable colorectal cancers. Cancer Res 65: 4607-4613, 2005.
68. Mitra A, Richardson RT and O'Rand MG: Analysis of recombinant human semenogelin as an inhibitor of human sperm motility. Biol Reprod 82: 489-496, 2010.
69. Canacci AM, Izumi K, Zheng Y, Gordetsky J, Yao JL and Miyamoto H: Expression of semenogelins I and II and its prognostic significance in human prostate cancer. Prostate 71: 1108-1114, 2011.
70. Santagata S, Maire CL, Idbaih A, Geffers L, Correll M, Holton K, Quackenbush J and Ligon KL: CRX is a diagnostic marker of retinal and pineal lineage tumors. PLoS One 4: e7932, 2009.
71. Glubrecht DD, Kim JH, Russell L, Bamforth JS and Godbout R: Differential CRX and OTX2 expression in human retina and retinoblastoma. J Neurochem 111: 250-263, 2009.
72. Terry J, Calicchio ML, Rodriguez-Galindo C and Perez-Atayde AR: Immunohistochemical expression of CRX in extracranial malignant small round cell tumors. Am J Surg Pathol 36: 1165-1169, 2012.
73. Yousef GM, Scorilas A, Jung K, Ashworth LK and Diamandis EP: Molecular cloning of the human kallikrein 15 gene (KLK15). J Biol Chem 276: 53-61, 2001.
74. Yousef GM, Scorilas A, Katsaros D, Fracchioli S, Iskander L, Borgono C, Rigault de la Longrais IA, Puopolo M, Massobrio M and Diamandis EP: Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. J Clin Oncol 21: 3119-3126, 2003.
75. Rabien A, Fritzsche FR, Jung M, Tölle A, Diamandis EP, Miller K, Jung K, Kristiansen G and Stephan C: KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy. Int J Cancer 127: 2386-2394, 2010.
76. Yousef GM, Scorilas A, Magklara A, Memari N, Ponzone R, Sismondi P, Biglia N, Abd Ellatif M and Diamandis EP: The androgen-regulated gene human kallikrein 15 (KLK15) is an indpendent and favourable prognostic marker for breast cancer. Br J Cancer 87: 1294-1300, 2002.
77. Kudo Y, Ogawa I, Kitajima S, Kitagawa M, Kawai H, Gaffney PM, Miyauchi M and Takata T: Periotin promotes invasion and anchorage-independent growth in the metastatic process of head and neck cancer. Cancer Res 66: 6928-6935, 2006.
78. Malanchi I, Santamaria-Martínez A, Susanto E, Peng H, Lehr HA, Delaloye JF and Huelsken J: Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481: 85-89, 2011.
79. Kanno A, Satoh K, Masamune A, Hirota M, Kimura K, Umino J, Hamada S, Satoh A, Egawa S, Motoi F, Unno M and Shimosegawa T: Periostin, secreted from stromal cells, has biphasic effect on cell migration and correlates with the epitelial to mesenchymal transition of human pancreatic cancer cells. Int J Cancer 22: 2707-2718, 2008.
80. Kyutoku M, Taniyama Y, Katsuragi N, Shimizu H, Kunugiza Y, Iekushi K, Koibuchi N, Sanada F, Oshita Y and Morishita R: Role of periostin in cancer progression and metastasis: Inhibition of breast progression and metastasis by anti-periostin antibody in a murine model. Int J Mol Med 28: 181-186, 2011.
81. Carter H, Samayoa J, Hruban RH and Karchin R: Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM). Cancer Biol Ther 10: 582-587, 2010.
82. Li Q, Wang L, Tan W, Peng Z, Luo Y, Zhang Y, Zhang G, Na D, Jin P, Shi T, Ma D and Wang L: Identification of C1qTNF-related protein 4 as a potential cytokine that stimulates the STAT3 and NF-κB pathways and promotes cell survival in human cancer cells. Cancer Lett 28: 203-214, 2011.
83. Belirgen M, Berrak SG, Ozdag H, Bozkurt SU, Eksioglu-Demiralp E and Ozek MM: Biologic tumor behavior in pilocytic astrocytomas. Childs Nerv Syst 28: 375-389, 2012.
84. Huang YW, Jansen RA, Fabbri E, Potter D, Liyanarachchi S, Chan MW, Liu JC, Crijns AP, Brown R, Nephew KP, van der Zee AG, Cohn DE, Yan PS, Huang TH and Lin HJ: Identification of candidate epigenetic biomarkers for ovarian cancer detection. Oncol Rep 22: 853-861, 2009.
85. Heller G, Babinsky VN, Ziegler B, Weinzierl M, Noll C, Altenberger C, Müllauer L, Dekan G, Grin Y, Lang G, End-Pfützenreuter A, Steiner I, Zehetmayer S, Döme B, Arns BM, Fong KM, Wright CM, Yang IA, Klepetko W, Posch M, Zielinski CC and Zöchbauer-Müller S: Genome-wide CpG island methylation analyses in non-small cell lung cancer patients. Carcinogenesis 34: 513-521, 2013.
86. Wirth T, Soeth E, Czubayko F and Juhl H: Inhibition of endogenous carcinoembryonic antigen (CEA) increases the apoptotic rate of colon cancer cells and inhibits metastatic tumor growth. Clin Exp Metastasis 19: 155-160, 2002.
87. Arrieta O, Saavedra-Perez D, Kuri R, Aviles-Salas A, Martinez L, Mendoza-Posada D, Castillo P, Astorga A, Guzman E and de la Garza J: Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis. BMC Cancer 9: 119-128, 2009.
88. Liebhardt S, Ditsch N, Nieuwland R, Rank A, Jeschke U, Von Koch F, Friese K and Toth B: CEA-, Her2/neu-, BCRP-and Hsp27-positive microparticles in breast cancer patients. Anticancer Res 30: 1707-1712, 2010.